A Phase 4 interventional study of Pramipexole and Placebo in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 42 sites in 9 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-06-27.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.
Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 6th largest by enrollment, is the only one that started in 2007, is one of 8 in phase 4, and was the 12th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2002; this study’s year is marked. 1 started in 2007.
This study's enrollment of 331 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 154 across the 17 interventional studies. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 5 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
21 studies in Restless Legs Syndrome by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 21 studies in Restless Legs Syndrome by Boehringer Ingelheim, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2007, is one of 4 in phase 4, and was the 11th registered.
Boehringer Ingelheim’s Restless Legs Syndrome studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing pramipexole in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 21 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the current study will be the evaluation of long-term efficacy of a 26-weeks treatment with pramipexole in patients with idiopathic moderate to severe Restless Legs Syndrome (RLS) in comparison to placebo.
The key secondary objectives are to assess the effects on clinical global impressions - global improvement (CGI-I) (based on CGI-I responder rate) and on RLS (based on IRLS responder rate) for 26 weeks under pramipexole in comparison to placebo. Further secondary objectives are to investigate the incidence and severity of augmentation and rebound and to assess the effects on patient global impression (PGI) (based on PGI responder rate), on RLS symptoms (based on the RLS-6 scales), on associated mood disturbance (based on item 10 of the IRLS), on pain in limbs (based on a visual analogue scale (VAS)), on quality of life in RLS (based on Johns Hopkins RLS-QoL), on general quality of life Short Form 36 (SF-36) and on safety (based on adverse events (AE) profile) of pramipexole in comparison to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.
Drug: Pramipexole
4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.
Drug: Placebo
Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks
IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe RLS symptoms)
Time frame: Baseline and 26 weeks
Clinical Global Impression - Global Improvement (CGI-I) Responder Rate
CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring 1 or 2 (at least much improved)
Time frame: after 26 weeks of treatment
International Restless Legs Syndrome (IRLS) Study Group Rating Scale Responder Rate
IRLS response was defined as at least 50% reduction in IRLS total score from baseline. IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe symptoms)
Time frame: after 26 weeks of treatment
Patient Global Impression (PGI) Responder Rate
PGI scores ranging from '1' (very much better) to '7' (very much worse), PGI responder have scoring 1 or 2 (at least much better)
Time frame: after 26 weeks of treatment
Change From Baseline in Restless Legs Syndrome-6 (RLS-6) Score "Satisfaction With Sleep" After 26 Weeks
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
Time frame: baseline and 26 weeks of treatment
Change From Baseline in RLS-6 Score "Severity Falling Asleep" After 26 Weeks
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
Time frame: Baseline and 26 weeks of treatment
Change From Baseline in RLS-6 Score "Severity During the Night" After 26 Weeks
The question was rated on an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
Time frame: baseline and 26 weeks of treatment
Change From Baseline in RLS-6 Score "Severity During the Day When at Rest" After 26 Weeks
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
Time frame: Baseline and 26 weeks of treatment
Change From Baseline RLS-6 Score "Severity During the Day Engaged in Activities" After 26 Weeks
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
Time frame: Baseline and 26 weeks of treatment
Change From Baseline in RLS-6 Score "Tired or Sleepy During the Day" After 26 Weeks
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
Time frame: Baseline and 26 weeks of treatment
Change From Baseline in IRLS Mood Disturbance Score (Item 10) After 26 Weeks
Mood disturbance associated with RLS symptoms ranging from 0 (none) to 4 (very severe)
Time frame: Baseline and 26 weeks of treatment
Change From Baseline in Visual Analogue Scale (VAS) Score for Pain in Limbs After 26 Weeks
The scale measures pain on a continuous 100 mm axis ranging from no pain (0 mm) to unbearable pain (100 mm)
Time frame: Baseline and 26 weeks of treatment
Change From Baseline in Quality of Life in RLS (RLS QoL) Score After 26 Weeks
RLS QoL total score ranging from 0 to 100 with higher values indicating better quality of life
Time frame: Baseline and 26 weeks of treatment
Change From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating less bodily pain
Time frame: Baseline and 26 weeks
Change From Baseline in SF-36 Dimension General Health After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating better health status
Time frame: Baseline and 26 weeks
Change From Baseline in SF-36 Dimension Mental Health After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating better mental health
Time frame: Baseline and 26 weeks
Change From Baseline in SF-36 Dimension Physical Functioning After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating better physical functioning
Time frame: Baseline and 26 weeks
Change From Baseline in SF-36 Dimension Role Limitations Due to Emotional Problems After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating less limitations due to emotional problems
Time frame: Baseline and 26 weeks
Change From Baseline in SF-36 Dimension Role Limitations Due to Physical Problems After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating less limitations due to physical problems
Time frame: Baseline and 26 weeks
Change From Baseline in SF-36 Dimension Social Functioning After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating better social functioning
Time frame: Baseline and 26 weeks
Change From Baseline in SF-36 Dimension Vitality After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating better vitality
Time frame: Baseline and 26 weeks
Change From Baseline in SF-36 Dimension Mental Component Summary After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating better health
Time frame: Baseline and 26 weeks
Change From Baseline in SF-36 Dimension Physical Component Summary After 26 Weeks
Score ranging from 0 to 100 with higher scores indicating better health
Time frame: Baseline and 26 weeks
Diagnosis of Classified Augmentation According to Independent Expert Panel
Augmentation is a worsening of RLS symptoms and may manifest as increased severity and the involvement of other extremities or as a shift of RLS symptoms to a time period that is 2 or more hours earlier than was typical of the time of symptom onset during the initial course of beneficial stable treatment or the state before recently starting treatment.
Time frame: after at least 4 weeks of treatment
Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation
Worsening of RLS symptoms, in comparison to baseline, following abrupt treatment discontinuation (for patients with no added RLS therapy after study drug discontinuation). Assessment of worsening of RLS was based on the IRLS total score assessed 7 ± 1 days after treatment discontinuation (the end of the study or premature discontinuation) compared with that at baseline. Analysis considered the number of patients experiencing a clinically relevant deterioration of ≥4 points in total IRLS score 7 ± 1 days after discontinuation of trial medication compared with baseline.
Time frame: after at least 1 week of treatment discontinuation
Baseline, Week 26 Mean Supine Systolic Blood Pressure
Time frame: Baseline, Week 26
Baseline, Week 26 Mean Standing Systolic Blood Pressure
Time frame: Baseline, Week 26
Baseline, Week 26 Mean Supine Diastolic Blood Pressure
Time frame: Baseline, Week 26
Baseline, Week 26 Mean Standing Diastolic Blood Pressure
Time frame: Baseline, Week 26
Baseline, Week 26 Mean Supine Pulse Rate
Time frame: Baseline, Week 26
Baseline, Week 26 Mean Standing Pulse Rate
Time frame: Baseline, Week 26
| Milestone | Pramipexole | Placebo |
|---|---|---|
| Started | 166 | 163 |
| Completed | 131 | 103 |
| Not completed | 35 | 60 |
| Withdrew: Adverse event | 19 | 23 |
| Withdrew: Lack of efficacy | 4 | 25 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Protocol violation | 3 | 2 |
| Withdrew: Withdrawal by subject | 6 | 5 |
| Withdrew: Personal reason | 0 | 1 |
| Withdrew: Patient was asymptomatic | 1 | 0 |
IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe RLS symptoms)
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks | -13.7 ± 0.8 | -11.1 ± 0.8 |
CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring 1 or 2 (at least much improved)
| participants | Pramipexole | Placebo |
|---|---|---|
| CGI-I responder (at least much improved) | 111 | 80 |
| CGI-I non-responder | 51 | 79 |
IRLS response was defined as at least 50% reduction in IRLS total score from baseline. IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe symptoms)
| participants | Pramipexole | Placebo |
|---|---|---|
| IRLS responder | 95 | 68 |
| IRLS non-responder | 67 | 91 |
PGI scores ranging from '1' (very much better) to '7' (very much worse), PGI responder have scoring 1 or 2 (at least much better)
| participants | Pramipexole | Placebo |
|---|---|---|
| PGI responder (much better or very much better) | 101 | 70 |
| PGI non-responder | 61 | 89 |
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in Restless Legs Syndrome-6 (RLS-6) Score "Satisfaction With Sleep" After 26 Weeks | -2.5 (-5.0 to 0.0) | -2 (-4.0 to 0.0) |
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in RLS-6 Score "Severity Falling Asleep" After 26 Weeks | -3 (-5.0 to 0.0) | -1 (-4 to 0.0) |
The question was rated on an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in RLS-6 Score "Severity During the Night" After 26 Weeks | -3 (-5.0 to 0.0) | -2 (-5.0 to 0.0) |
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in RLS-6 Score "Severity During the Day When at Rest" After 26 Weeks | -3 (-5.0 to 0.0) | -1 (-4.0 to 0.0) |
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline RLS-6 Score "Severity During the Day Engaged in Activities" After 26 Weeks | 0 (-1.0 to 0.0) | 0 (-1.0 to 0.0) |
The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in RLS-6 Score "Tired or Sleepy During the Day" After 26 Weeks | -1 (-3.0 to 0.0) | -1 (-3.0 to 0.0) |
Mood disturbance associated with RLS symptoms ranging from 0 (none) to 4 (very severe)
| scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in IRLS Mood Disturbance Score (Item 10) After 26 Weeks | -1 (-2.0 to 0.0) | -1 (-2.0 to 0.0) |
The scale measures pain on a continuous 100 mm axis ranging from no pain (0 mm) to unbearable pain (100 mm)
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in Visual Analogue Scale (VAS) Score for Pain in Limbs After 26 Weeks | -26 (-47.0 to -5.0) | -15 (-46.0 to 0.0) |
RLS QoL total score ranging from 0 to 100 with higher values indicating better quality of life
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in Quality of Life in RLS (RLS QoL) Score After 26 Weeks | 15 (5.0 to 25.0) | 12.5 (2.5 to 27.5) |
Score ranging from 0 to 100 with higher scores indicating less bodily pain
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks | 12 (0.0 to 31.0) | 9 (-1.0 to 24.5) |
Score ranging from 0 to 100 with higher scores indicating better health status
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in SF-36 Dimension General Health After 26 Weeks | 0 (-5.0 to 10.0) | 0 (-5.0 to 10.0) |
Score ranging from 0 to 100 with higher scores indicating better mental health
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in SF-36 Dimension Mental Health After 26 Weeks | 5 (-5.0 to 15.0) | 5 (-5.0 to 10.0) |
Score ranging from 0 to 100 with higher scores indicating better physical functioning
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in SF-36 Dimension Physical Functioning After 26 Weeks | 0 (0.0 to 10.0) | 0 (-5.0 to 10.0) |
Score ranging from 0 to 100 with higher scores indicating less limitations due to emotional problems
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in SF-36 Dimension Role Limitations Due to Emotional Problems After 26 Weeks | 0 (-8.3 to 16.7) | 0 (0.0 to 16.7) |
Score ranging from 0 to 100 with higher scores indicating less limitations due to physical problems
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in SF-36 Dimension Role Limitations Due to Physical Problems After 26 Weeks | 6.3 (0.0 to 18.8) | 6.3 (0.0 to 18.8) |
Score ranging from 0 to 100 with higher scores indicating better social functioning
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in SF-36 Dimension Social Functioning After 26 Weeks | 0 (0.0 to 12.5) | 0 (0.0 to 25.0) |
Score ranging from 0 to 100 with higher scores indicating better vitality
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in SF-36 Dimension Vitality After 26 Weeks | 6.3 (0.0 to 18.8) | 3.1 (-6.3 to 12.5) |
Score ranging from 0 to 100 with higher scores indicating better health
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in SF-36 Dimension Mental Component Summary After 26 Weeks | 1.7 (-2.4 to 8.3) | 1.9 (-2.3 to 6.7) |
Score ranging from 0 to 100 with higher scores indicating better health
| Scores on a scale | Pramipexole | Placebo |
|---|---|---|
| Change From Baseline in SF-36 Dimension Physical Component Summary After 26 Weeks | 2.1 (-0.5 to 7.5) | 2 (-2.0 to 5.9) |
Augmentation is a worsening of RLS symptoms and may manifest as increased severity and the involvement of other extremities or as a shift of RLS symptoms to a time period that is 2 or more hours earlier than was typical of the time of symptom onset during the initial course of beneficial stable treatment or the state before recently starting treatment.
| participants | Pramipexole | Placebo |
|---|---|---|
| Diagnosis of Classified Augmentation According to Independent Expert Panel | 18 | 14 |
Worsening of RLS symptoms, in comparison to baseline, following abrupt treatment discontinuation (for patients with no added RLS therapy after study drug discontinuation). Assessment of worsening of RLS was based on the IRLS total score assessed 7 ± 1 days after treatment discontinuation (the end of the study or premature discontinuation) compared with that at baseline. Analysis considered the number of patients experiencing a clinically relevant deterioration of ≥4 points in total IRLS score 7 ± 1 days after discontinuation of trial medication compared with baseline.
| participants | Pramipexole | Placebo |
|---|---|---|
| Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation | 14 | 2 |
| mm Hg | Pramipexole | Placebo |
|---|---|---|
| Baseline | 133.4 ± 16.9 | 132.7 ± 18.4 |
| Week 26 | 132.3 ± 16.4 | 132.2 ± 16.5 |
| mm Hg | Pramipexole | Placebo |
|---|---|---|
| Baseline | 132.6 ± 17.3 | 130.6 ± 18.2 |
| Week 26 | 132.4 ± 18.2 | 130.1 ± 17.1 |
| mm Hg | Pramipexole | Placebo |
|---|---|---|
| Baseline | 79.2 ± 9.7 | 79.6 ± 9.7 |
| Week 26 | 78.3 ± 9.7 | 79.5 ± 9.4 |
| mm Hg | Pramipexole | Placebo |
|---|---|---|
| Baseline | 82.7 ± 10.5 | 81.7 ± 10.7 |
| Week 26 | 80.5 ± 10.6 | 80.8 ± 10.0 |
| bpm | Pramipexole | Placebo |
|---|---|---|
| Baseline | 68.5 ± 9.6 | 68.7 ± 10.6 |
| Week 26 | 69.1 ± 8.9 | 68.3 ± 10.6 |
| bpm | Pramipexole | Placebo |
|---|---|---|
| Baseline | 74.6 ± 10.2 | 74.0 ± 10.7 |
| Week 26 | 74.1 ± 8.9 | 75.0 ± 10.6 |
Collected over 26 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pramipexole | — | 8/166 (4.8%) | 70/166 (42.2%) |
| Placebo | — | 3/163 (1.8%) | 58/163 (35.6%) |
| Event | Pramipexole | Placebo |
|---|---|---|
| AppendicitisInfections and infestations | 0/166 | 1/163 |
| Viral infectionInfections and infestations | 0/166 | 1/163 |
| Orthostatic hypotensionVascular disorders | 0/166 | 1/163 |
| Crohn's diseaseGastrointestinal disorders | 0/166 | 1/163 |
| VomitingGastrointestinal disorders | 0/166 | 1/163 |
| Urinary tract infectionInfections and infestations | 1/166 | 0/163 |
| Myocardial infarctionCardiac disorders | 1/166 | 0/163 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/166 | 0/163 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/166 | 0/163 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/166 | 0/163 |
| Event | Pramipexole | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 24/166 | 6/163 |
| FatigueGeneral disorders | 18/166 | 15/163 |
| HeadacheNervous system disorders | 13/166 | 17/163 |
| Restless legs syndromeNervous system disorders | 11/166 | 11/163 |
| SomnolenceNervous system disorders | 11/166 | 8/163 |
| NasopharyngitisInfections and infestations | 7/166 | 10/163 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 10/166 | 4/163 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/166 | 2/163 |
| Age, Continuous(years) | Pramipexole | Placebo | Total |
|---|---|---|---|
| Mean | 57.9 ± 12.7 | 55.8 ± 11.4 | 56.8 ± 12.1 |
| Sex: Female, Male(Participants) | Pramipexole | Placebo | Total |
|---|---|---|---|
| Female | 102 | 94 | 196 |
| Male | 64 | 69 | 133 |
The record gives a start of May 2007 and a primary completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole